Boston Scientific (NYSE:BSX) Given New $128.00 Price Target at Robert W. Baird

Boston Scientific (NYSE:BSX) had its price target raised by Robert W. Baird from $123.00 to $128.00 in a research note released on Wednesday morning, MarketBeat.com reports. They currently have an outperform rating on the medical equipment provider’s stock.

A number of other brokerages also recently issued reports on BSX. Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Raymond James Financial increased their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $120.67.

Boston Scientific Stock Down 1.9%

NYSE:BSX opened at $95.78 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock’s 50 day moving average price is $103.30 and its two-hundred day moving average price is $102.08. The firm has a market capitalization of $141.91 billion, a price-to-earnings ratio of 57.01, a price-to-earnings-growth ratio of 2.35 and a beta of 0.61. Boston Scientific has a twelve month low of $80.64 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. Insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its holdings in Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after buying an additional 3,932 shares during the period. Bank of New Hampshire lifted its holdings in Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after buying an additional 16,699 shares during the period. NS Partners Ltd lifted its holdings in Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after buying an additional 5,704 shares during the period. MRA Advisory Group acquired a new position in Boston Scientific during the 2nd quarter worth about $273,000. Finally, Neville Rodie & Shaw Inc. lifted its holdings in Boston Scientific by 95.9% during the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock worth $4,883,000 after buying an additional 22,255 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.